After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment
Back in March, AstraZeneca announced plans to halt a Phase III trial for its Farxiga drug ahead of schedule after seeing “overwhelming efficacy” in patients with chronic kidney disease. Now, the British drugmaker is claiming a win after the drug met all primary and secondary endpoints.
The trial confirmed Farxiga, an SGLT2 inhibitor used to treat adults with type 2 diabetes, helped halt kidney disease progression. AstraZeneca tracked a composite primary endpoint that combined measurements on whether renal function improved and whether the drug reduced the risk of renal failure. The trial hit that endpoint.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters